Published in Gastroenterology on January 14, 2009
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Multimodality imaging probes: design and challenges. Chem Rev (2010) 2.61
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol (2012) 2.59
Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles. Cancer (2010) 1.54
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano (2013) 1.28
A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer (2010) 1.17
Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biol Med (2012) 1.07
Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. Semin Oncol (2011) 1.07
Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut (2011) 1.05
uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection. Theranostics (2013) 0.98
Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano (2011) 0.95
Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug release. Mol Pharm (2010) 0.95
Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors. Small (2013) 0.93
Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release (2010) 0.93
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev (2015) 0.92
Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta (2009) 0.92
Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol (2014) 0.90
Photoacoustic tomography and fluorescence molecular tomography: a comparative study based on indocyanine green. Med Phys (2012) 0.90
Photothermal ablation of pancreatic cancer cells with hybrid iron-oxide core gold-shell nanoparticles. Int J Nanomedicine (2013) 0.89
Image-guided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumors. ACS Nano (2013) 0.87
Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol Pharm (2013) 0.87
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. Clin Physiol Funct Imaging (2013) 0.87
Nanomedicine in GI. Am J Physiol Gastrointest Liver Physiol (2010) 0.87
Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles. Small (2013) 0.86
A novel tumor targeting drug carrier for optical imaging and therapy. Theranostics (2014) 0.86
A handheld fluorescence molecular tomography system for intraoperative optical imaging of tumor margins. Med Phys (2011) 0.86
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. ACS Nano (2015) 0.85
Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches. Adv Funct Mater (2016) 0.84
Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy. Theranostics (2013) 0.82
Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics (2015) 0.82
Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells. Nanomedicine (Lond) (2013) 0.81
Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Mol Cancer Ther (2013) 0.80
Diverse Applications of Nanomedicine. ACS Nano (2017) 0.80
Ultrashort echo time (UTE) imaging of receptor targeted magnetic iron oxide nanoparticles in mouse tumor models. J Magn Reson Imaging (2014) 0.79
Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Mol Imaging Biol (2016) 0.77
Hyperthermia treatment of tumors by mesenchymal stem cell-delivered superparamagnetic iron oxide nanoparticles. Int J Nanomedicine (2016) 0.77
Targeting the insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse models. Oncotarget (2016) 0.76
Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer. Int J Nanomedicine (2016) 0.76
Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys. Int J Nanomedicine (2015) 0.76
Molecular Imaging with MRI: Potential Application in Pancreatic Cancer. Biomed Res Int (2015) 0.75
Familial pancreatic cancer. Cancers (Basel) (2010) 0.75
Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. Cancer Lett (2016) 0.75
Targeted Delivery with Imaging Assessment of siRNA Expressing Nanocassettes into Cancer. Methods Mol Biol (2016) 0.75
Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer. J Nanobiotechnology (2016) 0.75
In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody. Int J Nanomedicine (2016) 0.75
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med (2006) 7.05
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Molecular imaging in cancer. Science (2006) 5.01
In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 4.94
Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett (2006) 3.94
Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology (2003) 3.71
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. Chem Commun (Camb) (2004) 2.24
Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med (2008) 2.06
Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans Nanobioscience (2004) 1.82
In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer (2006) 1.62
Locally advanced pancreatic cancer. J Clin Oncol (2005) 1.55
Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol (2004) 1.49
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47
The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol (1995) 1.47
Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer (1999) 1.34
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res (1993) 1.22
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry (1994) 1.16
Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res (2007) 1.15
The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem (2001) 1.14
Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer (2007) 1.12
Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells. Int J Oncol (2006) 1.08
Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor. J Biol Chem (2000) 0.91
Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis (1998) 0.89
Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. Hum Gene Ther (2005) 0.89
Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism. Lab Invest (2004) 0.88
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res (2008) 5.67
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol (2002) 4.93
The iPlant Collaborative: Cyberinfrastructure for Plant Biology. Front Plant Sci (2011) 4.16
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol (2005) 3.92
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol (2003) 3.90
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA (2005) 3.43
Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev (2008) 3.18
Large-scale synthesis of nearly monodisperse CdSe/CdS core/shell nanocrystals using air-stable reagents via successive ion layer adsorption and reaction. J Am Chem Soc (2003) 2.87
Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg (2008) 2.80
Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc (2008) 2.79
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Structural basis for the autoinhibition of talin in regulating integrin activation. Mol Cell (2008) 2.53
Bioimaging: second window for in vivo imaging. Nat Nanotechnol (2009) 2.48
Epidemiologic features of severe fever with thrombocytopenia syndrome in China, 2011-2012. Clin Infect Dis (2013) 2.46
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc (2007) 2.45
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther (2006) 2.38
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res (2004) 2.31
A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano (2010) 2.27
Multifunctional nanoparticles as coupled contrast agents. Nat Commun (2010) 2.23
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine (2008) 2.20
Self-assembled nanoparticle probes for recognition and detection of biomolecules. J Am Chem Soc (2002) 2.18
A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol (2004) 2.14
Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res (2003) 2.09
Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem Soc Rev (2010) 2.08
The changing field of locoregional treatment for breast cancer. Oncology (Williston Park) (2011) 2.03
Alloyed semiconductor quantum dots: tuning the optical properties without changing the particle size. J Am Chem Soc (2003) 2.00
Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc (2007) 1.98
Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. J Am Chem Soc (2007) 1.95
Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol (2006) 1.94
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small (2009) 1.93
Quantum-dot nanocrystals for ultrasensitive biological labeling and multicolor optical encoding. J Biomed Opt (2002) 1.92
Peptide-linked molecular beacons for efficient delivery and rapid mRNA detection in living cells. Nucleic Acids Res (2004) 1.89
A systematic examination of surface coatings on the optical and chemical properties of semiconductor quantum dots. Phys Chem Chem Phys (2006) 1.88
Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009) 1.86
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol (2012) 1.85
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg (2010) 1.83
Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg (2007) 1.82
EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res (2010) 1.79
Plasmonic fluorescent quantum dots. Nat Nanotechnol (2009) 1.74
Using solution-phase nanoparticles, surface-confined nanoparticle arrays and single nanoparticles as biological sensing platforms. J Fluoresc (2004) 1.73
A wireless brain-machine interface for real-time speech synthesis. PLoS One (2009) 1.73
Sustained normalization of high blood pressure in spontaneously hypertensive rats by implanted hemin pump. Hypertension (2006) 1.71
Involvement of vascular peroxidase 1 in angiotensin II-induced vascular smooth muscle cell proliferation. Cardiovasc Res (2011) 1.70
Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One (2010) 1.70
Migfilin, a molecular switch in regulation of integrin activation. J Biol Chem (2008) 1.68
EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila) (2011) 1.65
Counting single native biomolecules and intact viruses with color-coded nanoparticles. Anal Chem (2006) 1.64
Tuning the optical and electronic properties of colloidal nanocrystals by lattice strain. Nat Nanotechnol (2008) 1.63
Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn (2006) 1.63
Protein energetic conformational analysis from NMR chemical shifts (PECAN) and its use in determining secondary structural elements. J Biomol NMR (2005) 1.62
Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol (2010) 1.62
Laparoscopic distal pancreatectomy: trends and lessons learned through an 11-year experience. J Am Coll Surg (2012) 1.61
Spectroscopic tags using dye-embedded nanoparticles and surface-enhanced Raman scattering. Anal Chem (2003) 1.61
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
Probabilistic Identification of Spin Systems and their Assignments including Coil-Helix Inference as Output (PISTACHIO). J Biomol NMR (2005) 1.56
Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it? Ann Surg Oncol (2003) 1.56
Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A (2004) 1.56
Positive and negative emotional verbal stimuli elicit activity in the left amygdala. Neuroreport (2002) 1.55
Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia. Small (2008) 1.53